Literature DB >> 23414634

Metastatic carcinoid tumors--are we making the cut?

Kathryn E Coan1, Richard J Gray, Richard T Schlinkert, Barbara A Pockaj, Nabil Wasif.   

Abstract

BACKGROUND: Although controversial, surgical resection for metastatic carcinoid tumors (MCTs) can potentially prolong survival.
METHODS: Patients with MCTs were identified from the Surveillance, Epidemiology and End Results database. Patients undergoing surgery were compared to unresected patients.
RESULTS: Surgery was performed in 33% of patients. Predictors of surgery included age <50 years (odds ratio [OR], 2.4), low grade (OR, 3.1), and the appendix (OR, 36.2) or small intestine (OR, 27.2) as the primary site. Predictors of adverse survival included high grade (hazard ratio, 2.4) and no surgery (hazard ratio, 2.5) or surgery on only primary or distant disease (hazard ratio, 1.5) compared with surgery for both. Survival at 5 years was 5% with no surgery, 28% with surgery on either site, and 46% with surgery at both sites (P < .001).
CONCLUSIONS: Surgery for MCTs is more common in younger patients, those with low-grade disease, and those with small bowel or appendiceal primary tumors. Although selection bias cannot be excluded, these data lend support to "debulking" for MCT.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23414634     DOI: 10.1016/j.amjsurg.2012.05.036

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  2 in total

1.  EndoVascular Occlusion and Tumor Excision (EVOTE): a Hybrid Approach to Small-Bowel Neuroendocrine Tumors with Mesenteric Metastases.

Authors:  Julian K Horwitz; Michael L Marin; Richard R P Warner; Robert A Lookstein; Celia M Divino
Journal:  J Gastrointest Surg       Date:  2019-05-14       Impact factor: 3.452

2.  Spontaneous Regression of a Carcinoid Tumor following Pregnancy.

Authors:  A Sewpaul; D Bargiela; A James; S J Johnson; J J French
Journal:  Case Rep Endocrinol       Date:  2014-12-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.